Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
Posted: May 1, 2023 at 12:18 am
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.
Read more from the original source:
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
Posted in Global News Feed
Comments Off on Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
Posted: May 1, 2023 at 12:18 am
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.
Go here to read the rest:
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
Posted in Global News Feed
Comments Off on Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023
Posted: May 1, 2023 at 12:18 am
PALO ALTO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:
Posted in Global News Feed
Comments Off on Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023
Total number of shares and voting rights in Zealand Pharma at April 28, 2023
Posted: May 1, 2023 at 12:18 am
Company announcement – No. 18 / 2023
Continued here:
Total number of shares and voting rights in Zealand Pharma at April 28, 2023
Posted in Global News Feed
Comments Off on Total number of shares and voting rights in Zealand Pharma at April 28, 2023
Publication of a transparency notification received from Alychlo NV
Posted: May 1, 2023 at 12:18 am
Liege, Belgium, 28 April 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, with registered offices at Lembergsesteenweg 19. 9820 Merelbeke, on 25, April 2023.
See the original post here:
Publication of a transparency notification received from Alychlo NV
Posted in Global News Feed
Comments Off on Publication of a transparency notification received from Alychlo NV
AB Science reports its revenues for the year 2022 and provides an update on its activities
Posted: May 1, 2023 at 12:18 am
PRESS RELEASE
More:
AB Science reports its revenues for the year 2022 and provides an update on its activities
Posted in Global News Feed
Comments Off on AB Science reports its revenues for the year 2022 and provides an update on its activities
ObsEva Annual Report 2022
Posted: May 1, 2023 at 12:18 am
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Here is the original post:
ObsEva Annual Report 2022
Posted in Global News Feed
Comments Off on ObsEva Annual Report 2022
Plus Therapeutics Announces Reverse Stock Split
Posted: May 1, 2023 at 12:18 am
AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 1, 2023, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023 under the Company’s existing trading symbol, “PSTV.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 72941H509.
Continue reading here:
Plus Therapeutics Announces Reverse Stock Split
Posted in Global News Feed
Comments Off on Plus Therapeutics Announces Reverse Stock Split
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
Posted: May 1, 2023 at 12:18 am
Regulated Information - Denominator
Continue reading here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
Posted in Global News Feed
Comments Off on Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update
Posted: May 1, 2023 at 12:18 am
ISTANBUL, Turkey, April 28, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.‘s (OTC: PRTT) (“Company”) President Ali Yildiz addresses the Company’s shareholders with a corporate update on expansion and forward-looking progress.
Read more here:
Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update
Posted in Global News Feed
Comments Off on Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update